Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab-Based Treatment in Newly Diagnosed Multiple Myeloma With Renal Insufficiency
NCT04352205Phase 2Terminated
- Sponsor
- Emory University
- Start
- May 2020
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Emory University. Started May 2020; status: terminated.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04352205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352205.